Medicines Discovery Catapult has joined forces with the Cystic Fibrosis Trust to form the Cystic Fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR).
The CF Syndicate in AMR brings industry leaders and people affected by CF together with academics with expertise in CF and pulmonary infection.
CF is a life limiting disease affecting over 10,500 people in the UK. People with CF experience a build-up of thick sticky mucus in their lungs and other organs, which leads to the development of frequent and persistent infections. AMR is frequently seen in people with CF, who die from antibiotic failures. The discovery and development of new antimicrobials to treat infections associated with CF is therefore an urgent unmet need.
The collective, cross-sector expertise of the CF Syndicate in AMR enables new efforts in the discovery of CF antimicrobials, to accelerate translation to the clinic and to ultimately bring better treatment options to people affected by CF, faster.
Since launching in September 2019, the CF Syndicate in AMR has engaged with the UK CF infection research community in academia and industry to understand the challenges in the discovery and translation of novel antimicrobials to the clinic to treat infections associated with CF.
- No agreed preclinical screening and testing pathways, and a lack of robust preclinical models of CF
- Difficulty to access clinically relevant samples, which are essential for the screening and testing of new CF antimicrobials, before they can be tested in the clinic
To address these challenges, the CF Syndicate in AMR will catalyse new research efforts and build capacity in the following areas:
- Streamline and enable access to clinically relevant samples for the preclinical screening and testing of CF antimicrobials
- Map and validate the preclinical screening and testing pathways to provide faster routes to bring CF antimicrobials to the clinic
- Develop guidance for industry on the key characteristics and requirements that CF antimicrobials should meet in order to address the needs and priorities of people with CF, through the development of Target Product Profiles.